Therapeutic hemapheresis
Activities conducted between 2008 and 2012
Keywords:
PLASMAPHERESISAbstract
Thereapeutic hemapheresis procedures constitute an important tool for the treatment of a growing number of conditions – being it the first line treatment for certain pathologies, according to the guidelines of the American Society of Apheresis (ASFA). It uses extracorporeal circulation and in most cases centrifugations is done to separate the different components in the blood, and to remove antibodies, immune complexes and sometimes excess cells that produce the disease. It is a safe and effective therapy when carried out by trained staff, in areas specially equipped for such purpose. This study presents the experience of the apheresis team at the Department of Transfusion Medicine between 2008 and 2012, in terms of the diseased treated and the side effects associated to such procedures.
References
(1) Abel JJ, Rowntree LC, Turner BB. Plasma Removal with return of corpuscles. J Pharmacol Exp Ther 1914; 5:625-41.
(2) Tui C, Bartter FC, W right, Holt RB. Red cell reinfusion and frecuency of plasma donations; preliminar report of multiple donations in 8 weeks by each 6 donors. JAMA 1944; 124:331-6.
(3) Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, et al; Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010; 25(3):83-177.
(4) Taft EG, Babcock RB, Scharfman WB, Tartaglia AP. Plateletpheresis in the management of thrombocytosis. Blood 1977; 50(5):927-33.
(5) Adami R. Therapeutic thrombocytapheresis: a review of 132 patients. Int J Artif Organs 1993; 16(Suppl 5):183-4.
(6) McLeod BC, Strauss RG, Ciavarella D, Gilcher RO, Kasprisin DO, Kiprov DD, et al. Management of hematological disorders and cancer. J Clin Apher 1993; 8(4):211-30.
(7) Decaro J, Lemos F, Magri M. Historia de la medicina transfusional. Montevideo: UDELAR, Facultad de Medicina, 2010:87-113.
(8) Vázquez MA, Perdomo S, Perdomo A, Cardeza A, Pereira A. Hemaféresis: experiencia en niños. Hemoterapia 1994; 6:4-8.
(9) Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 2013; 28(3):145-284.
(10) Shaz BH, Linenberger ML, Bandarenko N, Winters JL, Kim HC, Marques MB, et al. Category IV indications for therapeutic apheresis: ASFA fourth special issue. J Clin Apher 2007; 22(3):176-80.
(11) Szczepiorkowski ZM, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, et al; American Society for Apheresis; Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2007; 22(3):106-75.
(12) Szczepiorkowski ZM, Shaz BH, Bandarenko N, Winters JL. The new approach to assignment of ASFA categories-introduction to the fourth special issue: clinical applications of therapeutic apheresis. J Clin Apher 2007; 22(3): 96-105.
(13) Caridian BCT. COBE Spectra Apheresis System Essentials. Therapeutic Apheresis Guide for use with COBE Spectra system versions 4.7, 5.1–5.9, 6.0–6.9, 7.0–7.9. Lakewood, Colorado US: Caridian BCT, 2008.
(14) Okafor C, Kalantarinia K. Vascular access considerations for therapeutic apheresis procedures. Semin Dial 2012; 25(2):140-4.
(15) McLeod BC. Plasma and plasma derivatives in therapeutic plasmapheresis. Transfusion 2012; 52(Suppl 1):38S-44S.
(16) Hester JP, McCullough J, Mishler JM, Szymanski IO. Dosage regimens for citrate anticoagulants. J Clin Apher 1983; 1(3):149-57.
(17) Bambauer R, Jutzler GA, Albrecht D, Keller HE, Kohler M. Indications of plasmapheresis and selection of different substitution solutions. Biomater Artif Cells Artif Organs 1989; 17(1):9-26.
(18) Kaplan AA. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis 2008; 52(6):1180-96
(19) Norda R, Stegmayr BG; Swedish Apheresis Group. Therapeutic apheresis in Sweden: update of epidemiology and adverse events. Transfus Apher Sci 2003; 29(2):159-66.
(2) Tui C, Bartter FC, W right, Holt RB. Red cell reinfusion and frecuency of plasma donations; preliminar report of multiple donations in 8 weeks by each 6 donors. JAMA 1944; 124:331-6.
(3) Szczepiorkowski ZM, Winters JL, Bandarenko N, Kim HC, Linenberger ML, Marques MB, et al; Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2010; 25(3):83-177.
(4) Taft EG, Babcock RB, Scharfman WB, Tartaglia AP. Plateletpheresis in the management of thrombocytosis. Blood 1977; 50(5):927-33.
(5) Adami R. Therapeutic thrombocytapheresis: a review of 132 patients. Int J Artif Organs 1993; 16(Suppl 5):183-4.
(6) McLeod BC, Strauss RG, Ciavarella D, Gilcher RO, Kasprisin DO, Kiprov DD, et al. Management of hematological disorders and cancer. J Clin Apher 1993; 8(4):211-30.
(7) Decaro J, Lemos F, Magri M. Historia de la medicina transfusional. Montevideo: UDELAR, Facultad de Medicina, 2010:87-113.
(8) Vázquez MA, Perdomo S, Perdomo A, Cardeza A, Pereira A. Hemaféresis: experiencia en niños. Hemoterapia 1994; 6:4-8.
(9) Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML, et al. Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher 2013; 28(3):145-284.
(10) Shaz BH, Linenberger ML, Bandarenko N, Winters JL, Kim HC, Marques MB, et al. Category IV indications for therapeutic apheresis: ASFA fourth special issue. J Clin Apher 2007; 22(3):176-80.
(11) Szczepiorkowski ZM, Bandarenko N, Kim HC, Linenberger ML, Marques MB, Sarode R, et al; American Society for Apheresis; Apheresis Applications Committee of the American Society for Apheresis. Guidelines on the use of therapeutic apheresis in clinical practice: evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis. J Clin Apher 2007; 22(3):106-75.
(12) Szczepiorkowski ZM, Shaz BH, Bandarenko N, Winters JL. The new approach to assignment of ASFA categories-introduction to the fourth special issue: clinical applications of therapeutic apheresis. J Clin Apher 2007; 22(3): 96-105.
(13) Caridian BCT. COBE Spectra Apheresis System Essentials. Therapeutic Apheresis Guide for use with COBE Spectra system versions 4.7, 5.1–5.9, 6.0–6.9, 7.0–7.9. Lakewood, Colorado US: Caridian BCT, 2008.
(14) Okafor C, Kalantarinia K. Vascular access considerations for therapeutic apheresis procedures. Semin Dial 2012; 25(2):140-4.
(15) McLeod BC. Plasma and plasma derivatives in therapeutic plasmapheresis. Transfusion 2012; 52(Suppl 1):38S-44S.
(16) Hester JP, McCullough J, Mishler JM, Szymanski IO. Dosage regimens for citrate anticoagulants. J Clin Apher 1983; 1(3):149-57.
(17) Bambauer R, Jutzler GA, Albrecht D, Keller HE, Kohler M. Indications of plasmapheresis and selection of different substitution solutions. Biomater Artif Cells Artif Organs 1989; 17(1):9-26.
(18) Kaplan AA. Therapeutic plasma exchange: core curriculum 2008. Am J Kidney Dis 2008; 52(6):1180-96
(19) Norda R, Stegmayr BG; Swedish Apheresis Group. Therapeutic apheresis in Sweden: update of epidemiology and adverse events. Transfus Apher Sci 2003; 29(2):159-66.
Downloads
Published
2014-12-31
How to Cite
1.
Insagaray J, Lemos F, Rodríguez Grecco I, Menyou A, Barindelli P, Rivas G, et al. Therapeutic hemapheresis: Activities conducted between 2008 and 2012. Rev. Méd. Urug. [Internet]. 2014 Dec. 31 [cited 2024 Sep. 7];30(4):255-60. Available from: https://revista.rmu.org.uy/index.php/rmu/article/view/233
Issue
Section
Casuistry
